News and reporting on lung cancer.
Data being presented at the upcoming AACR meeting show that Guardant's liquid biopsy test provided more accurate and rapid mutation detection than tissue genotyping.
Biocept will use its liquid biopsy assay to test cerebrospinal fluids of patients diagnosed with certain cancers and then compare results to standard methods.
The NGS assay is designed to help physicians to identify non-small cell lung cancer patients who may benefit from eight targeted therapies.
The company posted $25.8 million in revenues for the quarter, up from $19.6 million a year ago, as total genomic test volume grew 28 percent to 9,154 tests.
Researchers will first compare liquid with tissue-based tumor profiling before implementing it as a way to enroll patients into the targeted drug trials.
An analyst said the DetermaVu test could potentially be best in class for lung cancer diagnosis and that CMS could begin reimbursing for it in late 2020.
The company will use proceeds to support commercialization of its lung cancer liquid biopsy test, and to fund studies to cement reimbursement and adoption.
In PNAS this week: sepsis-related copy number changes, three-dimensional leaf transcriptomes of plants grow in dark or in light-dark cycles, and more.
In PLOS this week: microRNAs linked to brain metastasis risk in lung cancer, effects of Crohn's disease-linked mutation, and more.
In a recent publication, the researchers assessed clinical data from 3,000 late-stage NSCLC patients after performing DNA and RNA sequencing on their tissue samples.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.